Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab, Apatinib, and Irinotecan Liposome in Advanced Gastric Cancer
NCT06592287Phase 2Not yet recruiting
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib, irinotecan liposome injection in gastric cancer (GC). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranibirinotecan liposome injection
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06592287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592287.